Researchers meeting in Chicago are in support of what they believe potentially could be a potent new weapon in the battle against cancer: the body’s own immune system.
International research that was conducted discovered that a mix of two drugs that helped allow the immune system to fight the cancer- ipilimumab and nivolumab stopped the deadly skin cancer melanoma from progressing for almost a year in close to 60% of cases.
Melanoma, however, a skin cancer, spread to the liver, lymph, nodes, bone, lungs, and brain. Other research have shown hope in treating lung cancer. The study is being presented in Chicago at the yearly conference of the American Society of Clinical Oncology and published in the New England Journal Medicine.
“Immunotherapy drugs have already revolutionized melanoma treatment, and now we’re seeing how they might be even more powerful when they’re combined,” stated Dr. Steven O’Day.
“But the results also warrant caution — the nivolumab and ipilimumab combination used in this study came with greater side effects, which might offset its benefits for some patients. Physicians and patients will need to weigh these considerations carefully,” O’Day stated.